鍵凱科技(688356.SH):與泰坦科技簽訂戰略合作框架協議
格隆匯7月29日丨鍵凱科技(688356.SH)公佈,公司與泰坦科技(688133.SH)經友好協商,於近日達成戰略合作意向並簽署了《戰略合作框架協議》。泰坦科技將作為供應商以市場化手段為公司提供實驗室使用的科研試劑、科研儀器耗材、科研信息化及實驗室設計與建設服務;公司將為泰坦科技自主品牌Adamas旗下的聚乙二醇衍生物產品系列提供OEM生產服務,共同開拓聚乙二醇衍生物產品在科研市場的應用。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.